

Sheet 1 f

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

2370-63  
APPLICANT

BELL et al.  
FILING DATE

(Use several sheets if necessary)

SERIAL NO.

09/664,444

#6  
~~RECEIVED~~

~~FEB 15 2001~~

September 18, 2000

**U.S. PATENT DOCUMENTS**

---

**GROUP**

**TECH CENTER 1600/2300**

RECEIVED

FEB 15 2009

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

\*Examiner

Robert Fenn

Date Considered

7/8/02

**\*Examiner** Robert L. Evans **Date Entered** 10/10/2023  
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

#5

~~RECEIVED~~

**INFORMATION DISCLOSURE  
CITATION**

**ATTY. DOCKET NO.**

SERIAL NO.

2370-63

09/664,444

APPLICANT

FEB 13 2001

(Use several sheets if necessary)

BELL, et al.

FILING DATE

**FILED DATE**

GROUP

September

## GROUP

September 18, 2000

## **TECH CENTER 1600/2900**

September 18, 2000

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

- |    |  |
|----|--|
| R7 | · Abraham et al, "The Murine PKR Tumor....," Experimental Cell Research, Vol. 244, pp. 394-404 (1998), Article No. EX984201                            |
| R7 | · Abraham, et al, "Characterization of Transgenic Mice with Targeted....," The Journal of Biological Chemistry, Vol. 274, No. 9, pp. 5953-5962 (1999). |
| R7 | · Bereita et al, "Expression of the protein kinase PKR....," Oncogene, Vol. 12, pp. 1593-1596 (1996).  |
| R7 | · Donze et al, "Abrogation of translation initiation....," Oxford University Press, pp. 3828-3834.   |
| R7 | · Gale, Jr. et al, "Evidence That Hepatitis C. Virus....," Virology, Vol. 230, pp. 217-227 (1997).   |
| R7 | · Kumar et al, "Double-Stranded RNA-Activated Protein ..." Molecular and Cellular Biology, pp. 1116-1125 (1999).                                       |
| R7 | · Melyville et al, "The molecular chaperone hsp40....," Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 97-102 (1997).  |
| R7 | · Mundschau et al, "Endogenous inhibitors of hte dsRNA....," Biochimie, Vol. 96, pp. 792-800 (1994).   |
| R7 | · Savinova et al, "Abnormal levels and minimal activity....," The Int'l Journal of Biochemistry & Cell Biology.  |
| R7 | · Strong et al, "The molecular basis of viral oncolysis....," The EMBO Journal, Vol. 71, No. 12, pp. 3351-3362 (1998).                                 |
| R7 | · Stojdl et al, "Exploiting tumor-specific defects....," Nature Medicine, Vol. 6, No. 7, pp. 821-825 (2000).   |
| R7 | · Stojdl et al, "The Murine Double-Stranded RNA-Dependent Protein....," Journal of Virology, Vol. 74, No. 20, pp. 9580-9585 (2000).                    |

1000

Chart Form

**Date Considered**

~~7/8/02~~

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form BTO-FB-A820 (Also BTO-1449)

#7

RECEIVED

## INFORMATION DISCLOSURE

ATTY. DOCKET NO.

SERIAL NO.

CITATION

2370-63

MAY 03 2001

MAY 01 2001

APPLICANT

09/664,444

BELL et al

TECH CENTER 1600/2900

(Use several sheets if necessary)

FILING DATE

GROUP

September 18, 2000

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RZ	5,215,745	6/93	CSATARY, et al			
RZ	5,273,745	12/93	SCHIRRMACHER			
RZ	5,585,096	12/96	MARTUZA, et al			
RZ	5,602,023	2/1997	Csatary			
RZ	5,124,148	6/1992	Csatary et al			
RZ	5,677,178	10/1997	McCormick			
RZ	6,110,461	8/2000	Lee et al			

## FOREIGN PATENT DOCUMENTS

TRANSLATION

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
RZ	WO 97/01358	1/97	PCT			
RZ	WO 97/04805	2/97	PCT			
RZ	WO 94/18992	9/94	PCT			
RZ	WO 99/08692	2/25/99	PCT			
RZ	WO 94/25627	11/94	PCT			
RZ	JP (A) 58-116422	7/83	Japan			
RZ	WO 93/18790	9/30/1993	PCT			
RZ	WO 86/00811	2/13/1986	PCT			
RZ	WO 86/00529	1/30/1986	PCT			
RZ	WO 99/29343	6/17/1999	PCT			
RZ	WO 99/55345	11/4/1999	PCT			
RZ	WO 00/45853	8/10/2000	PCT			
RZ	0 564 121 A2	10/6/1993	European Patent Application			
RZ	1,069,144	5/17/1967	Great Britain			
RZ	WO 99/04026	1/28/1999	PCT			
RZ	WO 99/18799	4/22/1999	PCT		Listed in IDS	H 6
RZ	WO 97/26904	7/31/1997	PCT			
RZ	WO 96/03997	2/15/1996	PCT			
RZ	WO 95/32706	12/7/1995	PCT			
RZ	WO 89/07445	8/24/1989	PCT			

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Abraham et al, "The Murine PKR Tumor..." Experimental Cell Research, Vol. 244, pp. 394-404 (1998), Article No. EX984201
	Abraham, et al, "Characterization of Transgenic Mice with Targeted..." The Journal of Biological Chemistry, Vol. 274, No. 9, pp. 5953-5962 (1999).
	Beretta et al, "Expression of the protein kinase PKR..." Oncogene, Vol. 12, pp. 1593-1596 (1996).
	Donze et al, "Abrogation of translation initiation..." Oxford University Press, pp. 3828-3834.
	Gale, Jr. et al, "Evidence That Hepatitis C Virus..." Virology, Vol. 230, pp. 217-227 (1997).
	Kumar et al, "Double-Stranded RNA-Activated Protein ..." Molecular and Cellular Biology, pp. 1116-1125 (1999).

\* Duplicated in IDS-5


- 2 -

RECEIVED

## INFORMATION DISCLOSURE

ATTY. DOCKET NO.

SERIAL NO.



2370-63

09/664,444

MAY 03 2001

APPLICANT

BELL et al

TECH CENTER 1600/2900

FILING DATE

GROUP

September 18, 2000

## PATENT OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) continued ...

	✓ Melyille et al, "The molecular chaperone hsp40...," Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 97-102 (1997).
	✓ Mundschau et al, "Endogenous inhibitors of the dsRNA...," Biochimie, Vol. 96, pp. 792-800 (1994).
	✓ Savinova et al, "Abnormal levels and minimal activity...," The Int'l Journal of Biochemistry & Cell Biology.
	✓ Strong et al, "The molecular basis of viral oncolysis...," The EMBO Journal, Vol. 11, No. 12, pp. 3351-3362 (1996).
	✓ Stoidl et al, "Exploiting tumor-specific defects...," Nature Medicine, Vol. 6, No. 7, pp. 821-825 (2000).
	✓ Stoidl et al, "The Murine Double-Stranded RNA-Dependent Protein...," Journal of Virology, Vol. 74, No. 20, pp. 9580-9585 (2000).
	Kirn, D.H., et al, MOLECULAR MEDICINE TODAY, December 1996, p. 519-527, "Replicating Viruses as Selective Cancer Therapeutics,"
	Heise, C., et al, NATURE MEDICINE, Vol. 3, No. 6, June 1997, p. 639-645 "ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents"
	Zhang, Jian-Feng, et al, PROC. NATL. ACAD. SCI, Vol. 93, pp. 4513-4518, April 1996, "Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy"
	Katze, Michael G., TRENDS IN MICROBIOLOGY, Vol. 3, No. 2, February 1995, pp. 75-78, "Regulation of the interferon-induced PKR: can viruses cope?"
	Maheshwari, Rada K., et al, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 117, No. 1, November 30, 1983, pp 161-168, "Low Infectivity of Vesicular Stomatitis Virus (VSV) Particles Released from Interferon-Treated Cells is Related to Glycoprotein Deficiency"
	Chou, Joany, et al, PROC. NATL. ACAD. SCI. USA, Vol. 92, pp. 10516-10520, November 1995, "Association of a Mr 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation ...herpes simplex virus 1"
	Xu, Bo, et al, BLOOD, Vol. 84, No. 6, September 15, 1994, pp 1942-1949, "Primary Leukemia Cells Resistant to $\gamma$ -Interferon In Vitro are Defective in the Activation of the DNA-Binding Factor ...Factor 3"
	Petricoin III, Emanuel, et al, MOLECULAR AND CELLULAR BIOLOGY, Vol. 14, No. 2, Feb. 1994, pp. 1477-1486 "Human Cancer Cell Lines Express a Negative Transcriptional Regulator of the Interferon Regulatory Factor Family of DNA Binding Proteins"
	Symons, Julian A., et al, CELL, Vol. 81, pp. 551-560, May 19, 1995, "Vaccinia Virus Encodes a Soluble type I Interferon Receptor of Novel Structure and Broad Species Specificity"
	Linge, Claire, et al, CANCER RESEARCH 55, PP. 4099-4104, September 15, 1995, "Interferon System Defects in Human Malignant Melanoma"
	Machida, Haruhiko, et al, MICROBIOL. IMMUNOL., Vol. 23 (7), 643-650, 1979, "Effect of Nucleosides on Interferon Production and Development of Antiviral State Induced by Poly I ! Poly C"
	Tanaka, Nobuyuki, et al, CELL, Vol. 77, 829-839, Jun 17, 1994, "Cellular Commitment to Oncogene-Induced Transformation or Apoptosis Is Dependent on the Transcription Factor IRF-1
	SCIENCE, Vol. 274, October 18, 1996, pp. 342-343, "Will a Twist of Viral Fate Lead to a New Cancer Cure?"
	Bischoff, James R., et al, SCIENCE, Vol. 274, October 18, 1996, pp. 373-376, "An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells"
	Andreansky, Samita S., et al, PROC. NATL. ACAD. SCI. USA, Vol. 93, pp. 11313-11318, October 1996 Colloquium Paper, "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors"
	Gastl, Guenther, et al, CANCER RESEARCH 52, pp.6229-6236, November 15, 1992, "Retroviral Vector-mediated Lymphokine Gene Transfer into Human Renal ...Cells"
	Buller, R. Mark L., et al, VIROLOGY 164, 182-192 (1988), "Cell Proliferative Response to Vaccinia Virus Is Mediated by VGF"

\* duplicated in 1DS-5

RECEIVED

## INFORMATION DISCLOSURE

ATTY. DOCKET NO.

SERIAL NO.



2370-63

09/664,444

MAY 03 2001

APPLICANT

BELL et al

TECH CENTER 1600/2900

FILING DATE

GROUP

September 18, 2000

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) continued ...

	Child, Stephanie J., et al, <i>VIROLOGY</i> , 174, 625-629 (1990), "Insertional Inactivation of the large Subunit of Ribonucleotide Reductase Encoded by Vaccinia Virus Is Associated with Reduced Virulence <i>In Vivo</i> "
	Restifo, Nicholas P., et al, <i>THE JOURNAL OF EXPERIMENTAL MEDICINE</i> , Vol. 175, June 1992, pp. 1423-1431, "A Nonimmunogenic Sarcoma Transduced with the cDNA for Interferon ( Elicits CD8+ T Cells against the Wild-type Tumor...Presentation Capability"
	Buller, R.M.L., et al, <i>NATURE</i> , Vol. 317, October 31, 1985, pp.813-815, "Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype"
	Haines, G.K., et al, <i>VIRCHOWS ARCHIV B CELL PATHOL</i> , (1993) 63:289-295, "Correlation of the expression of double-stranded RNA-dependent protein kinase (p68) with differentiation in head and neck squamous cell carcinoma"
	James, C. David, et al, <i>CANCER RESEARCH</i> , 51, pp. 1684-1688, March 15, 1991, "Chromosome 9 Deletion Mapping Reveals Interferon $\alpha$ and Interferon $\beta$ -1 Gene Deletions in Human Glial Tumors"
	Arroyo, Pedro J., et al, <i>CANCER IMMUNOL IMMUNOTHER</i> , (1990) 31:305-311, "Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon $\alpha$ in a murine hepatic metastasis model"
	Zhang, Wei-Wei, et al, <i>CANCER GENE THERAPY</i> , Vol. 1, No. 1, 1994: pp. 5-13 "High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus"
	Korth, Marcus, J., et al, <i>GENE</i> , 170 (1996) 181-188, "Cloning, expression, and cellular localization of the oncogenic 58-kDa inhibitor of the RNA-activated human and mouse protein kinase"
	Barber, Glen N., et al, <i>PROC. NATL. ACAD. SCI. USA</i> , Vol. 91, pp. 4278-4282, May 1994 Biochemistry, "The 58-kilodalton inhibitor of the interferon-induced double-stranded RNA-activated protein kinase is a tetratricopeptide repeat protein with oncogenic properties"
	Mathews, Michael B., et al, <i>JOURNAL OF VIROLOGY</i> , Vol. 65, No. 11, Nov. 1991, p. 5657-5662, "Adenovirus Virus-Associated RNA and Translation Control"
	Imani, Farhad, et al, <i>PROC. NATL. ACAD. SCI. USA</i> , Vol. 85, pp. 7887-7891, November 1988 Biochemistry, "Inhibitory activity for the interferon-induced protein kinase is associated with the reovirus serotype ...protein"
	Tanaka, Nobuyuki, et al, <i>JOURNAL OF IMMUNOTHERAPY</i> , Vol. 16, No. 4 (1994) pp. 283-293, "Immunotherapy of a Vaccinia Colon Oncolysate Prepared with Interleukin-2 Gene-Encoded Vaccinia Virus and Interferon- $\alpha$ Increases the Survival of Mice Bearing Syngeneic Colon Adenocarcinoma"
	Csاتary M.D., Laszlo K., et al, <i>CANCER DETECTION AND PREVENTION</i> , 17(6):619-627 (1993), "Attenuated Veterinary Virus Vaccine for the Treatment of Cancer"
	Agent Cassel Ph.D, William A., et al, <i>CANCER</i> , Vol. 18, No. 7, pp. 863-868, July 1965, "Newcastle Disease Virus As An Antineoplastic"
	Schirrmacher, V., et al, <i>INSTITUT FOR IMMUNOLOGIC UND GENETIK AM DEUTSCHEN KREBSFORSCHUNGSZENTRUM</i> , 6900 HEIDELBERG, GERMANY, pp. 19-49, March 13, 1986, "Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy"
	Lorenz, Robert M., et al, <i>JOURNAL OF THE NATIONAL CANCER INSTITUTE</i> , Vol. 80, No. 16, October 19, 1988, pp. 1305-1312, "Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor- $\alpha$ and Augmentation of Its Cytotoxicity"
	Reichard, Kirk W., et al, <i>JOURNAL OF SURGICAL RESEARCH</i> , 52, 448-453 (1992), "Newcastle Disease Virus Selectively Kills Human Tumor Cells"
	Eaton, Monroe D., et al, <i>JOURNAL OF THE NATIONAL CANCER INSTITUTE</i> , Vol. 39, No. 6, December 1967, pp. 1089-1097, "Contribution of Antiviral Immunity to Oncolysis by Newcastle Disease Virus in a Murine Lymphoma"
	Beverley, P.C., et al, <i>INT. J. CANCER</i> , 11, 212-223 (1973), "Immune Responses In Mice To tumour Challenge After Immunization With NewCastle Disease Virus-Infected or X-Irradiated Tumour Cells or Cell Fractions"

## INFORMATION DISCLOSURE

ATTY. DOCKET NO.

SERIAL NO.

2370-63

09/664,444

APPLICANT

BELL et al

FILING DATE


GROUP

(Use several sheets if necessary)

September 18, 2000

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) continued ...

	Shoham, Jacob, et al, <i>NAT. IMMUN. CELL GROWTH REGUL.</i> , 1990; 9:165-172, "Augmentation of Tumor Cell Immunogenicity by Viruses - An Approach to Specific Immunotherapy of Cancer"
	Bart, Robert S., et al, <i>NATURE NEW BIOLOGY</i> , Vol. 245, No. 147, October 24, 1973, pp.229-230, "Role of Interferon in the Anti-Melanoma Effects of Poly(I).Poly (C) and Newcastle Disease Virus"
	Sinkovics, Joseph, et al, <i>INTERVIROLOGY</i> , 1993, 36:193-214, "New Developments in the Virus Therapy of Cancer: A Historical Review"
	Murray, Douglas R., et al, <i>CANCER</i> , August 1977, Vol. 40, No. 2, pp. 680-686, "Viral Oncolysate in the Management of Malignant Melanoma"
	Cassel, William A., <i>CANCER</i> , 52:856-860, Sept. 1, 1983, "A Phase II Study on the Postsurgical Management of Stag Malignant Melanoma With a Newcastle Disease Virus Oncolysate"
	Cassel, William A., <i>MED. ONCOL. &amp; TUMOR PHARMACOTHER.</i> , Vol. 9, No. 4, pp. 169-171, 1992, "A Ten-Year Follow-up on Stage II Malignant Melanoma Patients Treated Postsurgically with New Castle Disease Virus Oncolysate"
	Bohle, MD, Wolfran, et al, <i>CANCER</i> , Vol. 66, No. 7, pp. 1517-1523, Oct. 1, 1990 "Postoperative Active Specific Immunization in Colorectal Cancer Patients With Virus-Modified Autologous Tumor-Cell Vaccine"
	Eaton, Monroe D., et al, <i>INFECTION AND IMMUNITY</i> , Vol. 15, No. 1, Jan. 1977, pp. 322-328, "Autoimmunity Induced by Injection of Virus-Modified Cell Membrane Antigens in Syngeneic Mice"
	Wheelock, M.D., E. Frederick, et al, <i>THE NEW ENGLAND JOURNAL OF MEDICINE</i> , Vol. 271, No. 13, Sept. 24, 1964, pp. 645-651, "Observations on the Repeated Administration of Viruses to a Patient with Acute Leukemia"
	<i>THE LANCET</i> , October 9, 1971, p. 825, "Viruses in the Treatment of Cancer"
	Kenney, Shannon, et al, <i>JNCI EDITORIAL ISSUE</i> 16, June 20, 1997, pp. 1-3, June 20, 1997, "Viruses as Oncolytic Agents: a New Age for 'Therapeutic' Viruses?"
	Rodriguez, Ron, et al, <i>CANCER RESEARCH</i> , 57, 2559-2563, July 1, 1997, "Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective3 Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells"
	Martuza, MD, Robert, <i>EXAMINER</i> , October 1995, Georgetown University Medical Center, pp.1-8, "Novel Treatment Approach for Malignant Brain Tumors Developed at Georgetown"
	Mineta, Toshihiro, et al, <i>NATURE MEDICINE</i> , Vol. 1, No. 9, Sept. 1995, 938-943, "Attenuated Multi-Mutated Herpes Simplex Virus-1 for the Treatment of Malignant Gliomas"
	Zhenxiang, Huang, et al, <i>ACTA ACADEMIAE MEDICINE SINICAE</i> , Vol. 6, No. 3, June 1984, "Studies on Viral Immunotherapy of Ascitic Tumors in Mice. -- I. Results of Treatment on Viruses of Ehrlich and S180 Ascitic Tumor Cells" p. 213-216
	<i>Abstract</i> , 1362, Ganly, et al, <i>PROCEEDINGS OF ASCO</i> , Vol. 16 (1997), p. 433a "Phase I Trial of Intratumoral Injection with an E1B-Attenuated Adenovirus, ONYX-015, in Patients with Recurrent p53(-) Head and Neck Cancer"
	<i>Abstract</i> , 1564, Kirn, et al, <i>PROCEEDINGS OF ASCO</i> , Vol. 16 (1997), p. 433a "ONYX-015, A Selectively Replicating Adenovirus, Has Antitumoral Activity Following IV Administration Alone and in Combination with Chemotherapy"
	<i>Abstract</i> , 1554, Izbicka, et al, <i>PROCEEDINGS OF ASCO</i> , Vol. 16 (1997), p. 433a "Effects of ONYX Adenovirus Preparations on Human Tumor Colony Forming Units"
	<i>Abstract</i> , 2400, Kirn, et al, <i>PROCEEDINGS FOR THE AMERICAN ASSOCIATION FOR CANCER RESEARCH</i> , Vol 37, March 1996, p. 352 "ONYX-015 Selectively Replicates in and Lyses Cells Lacking Functional Small p53."
	Field, H.J., et al, <i>J. HYG., CAMB.</i> , 81, 267-277, (1978) "The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice"

INFORMATION DISCLOSURE		ATTY. DOCKET NO.	SERIAL NO.
 <small>(Use several sheets if necessary)</small>		2370-63	09/664,444
		APPLICANT	
		BELL et al	
		FILING DATE	GROUP
September 18, 2000			
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) continued ...			
		Spriggs, Dale R., et al, NATURE, Vol. 297, May 6, 1982, pp 68-70, "Attenuated reovirus type 3 strains generated by selection of haemagglutinin antigenic variants"	
		Goldstein, David J., et al, VIROLOGY, 166, 41-51 (1988), "Factor(s) present in Herpes Simplex Virus Type 1-Infected Cells Can Compensate for the Loss of the Large Subunit of the Viral Ribonucleotide Reductase: Characterization of an ICP6 Deletion Mutant"	
		Perkus, Marion E., et al, VIROLOGY, 180, 406-410 (1991), "Deletion of 55 Open Reading Frames from the Termini of Vaccinia Virus"	
		Meignier, Bernard, et al, JOURNAL OF INFECTIOUS DISEASES, 162: 313-321 (1990), "In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020. II. Studies in Immunocompetent and Immunosuppressed Owl Monkeys ( <i>Aotus trivirgatus</i> )"	
		Hughes, Stephen J., et al, JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 266, No. 30, Issue of October 25, 1991, pp. 20103-20109, "Vaccinia Virus Encodes an Active Thymidylate Kinase That Complements a <i>cdc8</i> Mutant of <i>Saccharomyces cerevisiae</i> "	
		Kerr, Shona M., et al, THE EMBO JOURNAL, Vol. 10, No. 13, pp. 4343-4350, (1991), "Vaccinia DNA ligase complements <i>Saccharomyces cerevisiae cdc9</i> , localizes in cytoplasmic factories and affects virulence and virus sensitivity to DNA damaging agents"	
		Clark, H. Fred, et al, JOURNAL OF INFECTIOUS DISEASES, Vol. 158, No. 3, September 1988, p. 570-587, "Protective Effect of WC3 Vaccine Against Rotavirus Diarrhea in Infants During a predominantly Serotype 1 Rotavirus Season"	
		Takafuji, Ernest T., et al, JOURNAL OF INFECTIOUS DISEASES, Vol. 140, No. 1, July 1979, pp.48-53, "Simultaneous Administration of Live, Enteric-Coated Adenovirus Types 4, 7, and 21 Vaccines: Safety and Immunogenicity"	
		Taylor, M.W., et al, JOURNAL OF THE NATIONAL CANCER INSTITUTE, Vol. 44, No. 3, March 1970, pp. 515-519, "Virus-Induced Regression of Tumor Growth"	
		Beattie, Elizabeth, et al, VIRUS GENES, 12:1, 89-94, 1996, "Host-Range Restriction of Vaccinia Virus E3L-Specific Deletion Mutants"	
		Howard, Brad, et al, ANNALS NEW YORK ACADEMY OF SCIENCES, Duke University Medical Center, p. 167-187, "Retrovirus-Mediated Gene Transfer of the Human (-IFN Gene: A Therapy for Cancer"	
		Suskind, R.G., et al, US Dept. of Health, Education, & Welfare, N.I.H., National Institute of Allergy and Infectious Diseases, and National Cancer Inst., Bethesda, Md. ONCOLYTIC EFFECT OF COXSACKIE VIRUS, pp. 309-318, "Viral Agents Oncolytic for Human Tumors in Heterologous Host. Oncolytic Effect of Coxsackie B. Viruses." (22932), October 29, 1956	
		Bluming, Avrum Z., et al, THE LANCET, July 10, 1971, p. 105-106 "Regression of Burkitt's Lymphoma ... Association With measles Infection"	
		Pasquinucci, G., THE LANCET, January 16, 1971, i, 136 "Possible Effect of Measles on Leukaemia"	
		Gross, Samuel, THE LANCET, February 20, 1971, p.397-398, "Measles and Leukaemia"	
		Shingu, M., JOURNAL OF GENERAL VIROLOGY (1991), 72, 2031-2034, "Therapeutic effects of bovine enterovirus infection on rabbits with experimentally induced adult T cell leukaemia"	
		Faaberg, Kay S., et al, JOURNAL OF VIROLOGY, Vol. 62, No. 2, p. 586-593, Feb. 1988, "Strain Variation and Nuclear Association of Newcastle Disease Virus Matrix Protein"	
		Holzaepfel, John H., et al, CANCER, May-June 1957, Vol. 10, pp. 577-580, "The Use of APC3 Virus As A Cancericidal Agent"	
		Smith, Robert R., MD, et al, CANCER, November-December 1956, Vol. 9, pp. 1211-1218, "Studies on the Use of Viruses in the Treatment of Carcinoma of the Cervix"	
		Rukavishnikova, G.E., et al, ACTA VIROL., 20:387-394, 1976, "Some Immunological Mechanisms of the Influenza Virus Antitumour Effect"	

## INFORMATION DISCLOSURE

ATTY. DOCKET NO.

SERIAL NO.

2370-63

09/664,444

APPLICANT

BELL et al

(Use several sheets if necessary)

FILING DATE

GROUP

PATENTS TRADES

September 18, 2000

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) continued ...

	Kalvakolanu, D.V.R., et al, PROC. NATL. ACAD. SCI. USA, Vol. 90, pp. 3167-3171, April 1993, "Differentiation-dependent activation of interferon-stimulated gene factors and transcription factor NF- $\kappa$ B in mouse embryonal carcinoma cells"
	Foy, Teresa M., et al, J. EXP. MED. © The Rockefeller University Press - 0022-1007/93/11/1567/09, Volume 178, November 1993, pp. 1567-1575, "In Vivo CD40-gp39 Interactions are Essential for Thymus-dependent Humoral Immunity. II. Prolonged Suppression of the Humoral Immune Response by an Antibody to the Ligand for CD40, gp39"
	Blaese, R.M., et al, EUROPEAN JOURNAL OF CANCER, Vol. 30A, No. 8, pp. 1190-1193, 1994, "In situ Delivery of Suicide Genes for Cancer Treatment"
	Zhang, Jian Feng, et al, CANCER GENE THERAPY, Vol. 3, No. 1, 1996, pp. 31-38, "Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression"
	Peplinski, Gary R., et al, ANNALS OF SURGICAL ONCOLOGY, 3(2):15-23, "Prevention of Murine Breast Cancer by Vaccination with Tumor Cells Modified by Cytoline-Producing Recombinant Vaccinia Viruses"
	Cotran, Ramzi S., M.D., et al, ROBBINS PATHOLOGIC BASIS OF DISEASE, 4th Edition, p. 251, "Kinetics of Tumor Cell Growth"
	Schloer, G.M., et al, JOURNAL OF VIROLOGY, Vol. 2, No. 1, Jan. 1968, pp. 40-47, "Relationship of Plaque Size and Virulence for Chickens of 14 Representative Newcastle Disease Virus Strains"
	Tait, David L., et al, CLINICAL CANCER RESEARCH, Vol. 3, pp. 1959-1968, November 1997, "A Phase I Trial of Retroviral BRCA1sv Gene Therapy in Ovarian Cancer"
	Martuza, Robert L., et al, SCIENCE, Vol. 252, pp. 854-855, May 10, 1991, "Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant"
	Hanson, R.P., et al, SCIENCE, Vol. 122, pp. 156-157, July 22, 1955, "Identification of Vaccine Strains of Newcastle Disease Virus"
	Chambers, Renee, et al, PROC. NATL. ACAD. SCI. USA, Vol. 92, pp. 1411-1415, February 1995, "Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma"
	Asada, Teruo, MD, CANCER, Vol. 34, pp. 1907-1928, December 1974, "Treatment of Human Cancer with Mumps Virus"
	Sreevalsan, Thazepadath, BIOLOGIC THERAPY OF CANCER: PRINCIPLES AND PRACTICE, pp. 347-364, Chapter 14 Biologic Therapy with Interferon- $\alpha$ and $\beta$ : Preclinical Studies
	Stoner, Gary D., et al, NATURE, Vol. 245, October 12, 1973, pp. 319-320, "Effect of Neuraminidase pretreatment on the Susceptibility of Normal and Transformed Mammalian Cells to Bovine Enterovirus 261"
	Joklik, W.K., VIROLOGY, Second Edition 1990, pp. 383-410, "Interferons"
	Schnell, Matthias, J., et al, CELL, Vol. 90, pp. 849-857, September 5, 1997, "Construction of a Novel Virus that Targets HIV-1-Infected Cells and Controls HIV-1 Infection"
PL	Lorenz, Robert M., et al, JOURNAL OF THE NATIONAL CANCER INSTITUTE, Vol. 86, No. 16, August 17, 1994, pp. 1228-1233, "Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy"
	Kirchner, H.H., et al, WORLD J UROL. (1995) 13:171-173, "Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines"
	Murphy, Frederick A., et al, VIROLOGY, Second Edition, 1990, Chapter 2, pp. 9-35, "Virus Taxonomy"
	Csatary, Laszlo K., THE LANCET, October 9, 1971, p. 825, "Viruses in the Treatment of Cancer"
PL	Ahlert, T., et al, CANCER RES. 50 (1990), pp. 5962-5968, "Isolation of a Human Melanoma Adapted Newcastle Disease Virus Mutant with Highly Selective Replication Patterns"
	HASHIRO, G., et al, Archives of Virology 54, 307-315 (1977) "The Preferential Cytotoxicity of Reovirus for Certain Transformed Cell Lines"



## INFORMATION DISCLOSURE

ATTY. DOCKET NO.

SERIAL NO.

## CITATION

2370-63

09/664,444

APPLICANT

BELL et al

FILING DATE

GROUP

(Use several sheets if necessary)

September 18, 2000

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, etc.) continued ...

R2	Lorenz, R.M., et al, <u>Cancer Research</u> , 54: 6017-6021, December 1, 1994 "Complete Regression of Human Fibrosarcomas Xenografts after Local Newcastle Disease Virus Therapy"
	Database CAPLUS, on STN Columbus (OH):chemical abstract service, DN 116: 104333, CN 1054192 A. ZHENG, B., "Attenuated new castle disease virus for induction of interferons to combat neoplasm or viral diseases," Abstract, 09 April 1991
	GRESSER, et al, "Exogenous Interferon and Inducers of Interferon in the Treatment of Balb/c Mice Inoculated with RC19 Tumor Cells," <u>Nature</u> , 23 August 1969, Vol. 223, pps. 844-845
	CSATARY, L.K., et al, <u>Orvosi Hetilap</u> 131: 2585-2588, 1990, "Virus Vaccines For The Treatment of Cancer"
	Eck et al, Gene-Based Therapy. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9 <sup>th</sup> Edition, chapter 5 (1996).
	Verma et al. Gene Therapy-Promises, Problems, and Prospects. <u>Nature</u> , vol. 389, pages 239-242 (1997)

\*Examiner

*Robert Egan*

Date Considered

*7/8/02*

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

48

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO.	SERIAL NO.			
		2370-63	09/664,444			
		APPLICANT	MAY 30 2001			
		BELL et al.	RECEIVED			
(Use several sheets if necessary)		FILING DATE	TECH CENTER 1600/2900			
MAY 15 2001 O I P E S C I T Y P A T E N T & T R A D E M A R K O F F I C E		September 18, 2000				
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
RZ	96/26285	8/1996	WO			
RZ	94/19022	9/1994	WO			X
RZ	99/18799	4/1999	WO			
KT	99/45783	9/1999	WO			
ICR	96/34625	11/1996	WO			
ICR	00/62735	10/2000	WO			
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)						
RZ	Sinkovics et al, "New Developments in the Virus Therapy of Cancer: A Historical Review," <i>Intervirology</i> , Vol. 36, pp. 193-214 (1993).					
RZ	XP-002164069, Horvath et al, "Comparison of oncolytic Newcastle Disease Virus strains," <i>Cancer Institute, St. Joseph's Hospital, Tampa, Florida</i> . No date					
RZ	Restifo et al, "A Nonimmunogenic Sarcoma Transduced with the cDNA...," <i>The Journal of Experimental Medicine</i> , Vol. 175, pp. 1423-1431 (1992).					
RZ	Beattie et al, "Host-Range Restriction of Vaccinia Virus...," <i>Virus Genes</i> , Vol. 21, No. 1, pp. 89-94 (1996).					
RZ	Arroyo et al, "Active specific immunotherapy with vaccinia colon...," <i>Cancer Immunol Immunother</i> , Vol. 31, pp. 305-311 (1990).					
RZ	Yu et al, "Antiviral action of interferon-β on...," <i>Med Microbial Immunol</i> , Vol. 184, pp. 45-52 (1995).					
RZ	Nickels et al, "Identification of an amino acid change that affects...," <i>Journal of General Virology</i> , Vol. 75, pp. 3591-3595 (1995).					
RZ	Schubert et al, "Primary Structure of the Vesicular...," <i>Journal of Virology</i> , Aug. 1984, pp. 505-514.					
RZ	Balachandran et al, "Activation of the dsRNA-dependent protein...," <i>The EMBO Journal</i> , Vol. 17, No. 23, pp. 6888-6902 (1998).					
RZ	Durbin et al, "Targeted Disruption of the Mouse <i>Stat1</i> Gene Results...," <i>Cell</i> , Vol. 84, pp. 443-450 (1996).					
RZ	Stojdl et al, "Exploiting tumor-specific defects in the interferon pathway...," <i>Nature Medicine</i> , Vol. 6, No. 7, pp. 821-825 (2000).					
RZ	Balachandran et al, "Vesicular Stomatitis Virus...," <i>Life</i> , Vol. 50, pp. 135-138 (2000).					
RZ	Francoeur et al, "The Isolation of Interferon-Inducing Mutants of...," <i>Virology</i> , Vol. 160, pp. 236-245 (1987).					
*Examiner Signature		Date Considered		7/8/02		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)